Seres Therapeutics Stock Probability Of Bankruptcy

MCRB Stock

USD 0.76 0.02 2.32%

Seres Therapeutics' chance of distress is over 65% at the present time. It has high odds to experience some financial hardship in the next few years. Chance of distress shows the probability of financial torment over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Seres balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Seres Therapeutics Piotroski F Score and Seres Therapeutics Altman Z Score analysis.

For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.

As of February 26, 2025, Market Cap is expected to decline to about 195.8 M. In addition to that, Enterprise Value is expected to decline to about 289.7 M

Seres Therapeutics Company chance of distress Analysis

Seres Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Seres Therapeutics Probability Of Bankruptcy

Over 76%

Most of Seres Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seres Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of Seres Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Seres Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Seres Therapeutics financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.40)

Revenue Per Share

0.871

Quarterly Revenue Growth

(0.93)

Return On Assets

(0.1)

Return On Equity

(15.56)

The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Short Term Investments	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock	Net Receivables	Long Term Debt Total
Total Assets		0.29	0.14	-0.82	0.65	0.75	0.92	0.82	0.44	0.61	0.63	0.72	0.54	-0.43	0.35	-0.46	-0.82	0.85	0.41	0.23	0.8	0.67	0.63
Total Stockholder Equity	0.29		-0.55	0.2	0.25	-0.34	0.55	-0.13	0.26	-0.41	0.29	0.15	0.95	0.61	-0.43	0.44	-0.29	-0.07	0.62	0.68	-0.21	-0.13	-0.37
Net Debt	0.14	-0.55		-0.49	-0.18	0.57	-0.18	0.56	-0.24	0.75	-0.18	0.02	-0.37	-0.58	0.23	-0.36	-0.06	0.39	-0.18	-0.41	0.56	0.57	0.69
Retained Earnings	-0.82	0.2	-0.49		-0.56	-0.94	-0.62	-0.97	-0.4	-0.88	-0.5	-0.62	-0.06	0.81	-0.52	0.73	0.71	-0.91	-0.14	0.05	-0.93	-0.75	-0.78
Accounts Payable	0.65	0.25	-0.18	-0.56		0.46	0.69	0.51	0.36	0.22	0.6	0.71	0.34	-0.34	0.25	-0.57	-0.67	0.49	0.14	0.18	0.41	0.18	0.3
Total Liab	0.75	-0.34	0.57	-0.94	0.46		0.55	0.95	0.29	0.94	0.44	0.58	-0.04	-0.82	0.51	-0.72	-0.6	0.81	0.06	-0.13	0.88	0.7	0.78
Total Current Assets	0.92	0.55	-0.18	-0.62	0.69	0.55		0.64	0.58	0.36	0.72	0.7	0.75	-0.19	0.16	-0.31	-0.81	0.63	0.53	0.45	0.55	0.41	0.3
Common Stock	0.82	-0.13	0.56	-0.97	0.51	0.95	0.64		0.38	0.92	0.47	0.57	0.15	-0.75	0.41	-0.66	-0.69	0.87	0.21	0.01	0.93	0.76	0.77
Current Deferred Revenue	0.44	0.26	-0.24	-0.4	0.36	0.29	0.58	0.38		0.17	0.69	0.6	0.37	-0.32	0.24	-0.36	-0.77	0.21	0.0	0.05	0.17	0.08	-0.14
Long Term Debt	0.61	-0.41	0.75	-0.88	0.22	0.94	0.36	0.92	0.17		0.3	0.37	-0.13	-0.82	0.37	-0.62	-0.46	0.76	0.03	-0.19	0.87	0.73	0.81
Short Term Debt	0.63	0.29	-0.18	-0.5	0.6	0.44	0.72	0.47	0.69	0.3		0.86	0.46	-0.38	0.23	-0.6	-0.83	0.36	0.04	0.09	0.28	0.04	0.11
Property Plant Equipment	0.72	0.15	0.02	-0.62	0.71	0.58	0.7	0.57	0.6	0.37	0.86		0.33	-0.44	0.52	-0.68	-0.85	0.47	0.02	0.01	0.42	0.18	0.3
Net Tangible Assets	0.54	0.95	-0.37	-0.06	0.34	-0.04	0.75	0.15	0.37	-0.13	0.46	0.33		0.38	-0.34	0.25	-0.5	0.15	0.64	0.63	0.04	0.08	-0.15
Short Term Investments	-0.43	0.61	-0.58	0.81	-0.34	-0.82	-0.19	-0.75	-0.32	-0.82	-0.38	-0.44	0.38		-0.43	0.82	0.53	-0.59	0.44	0.57	-0.69	-0.53	-0.7
Deferred Long Term Liab	0.35	-0.43	0.23	-0.52	0.25	0.51	0.16	0.41	0.24	0.37	0.23	0.52	-0.34	-0.43		-0.49	-0.26	0.51	0.03	-0.06	0.48	0.38	0.37
Long Term Investments	-0.46	0.44	-0.36	0.73	-0.57	-0.72	-0.31	-0.66	-0.36	-0.62	-0.6	-0.68	0.25	0.82	-0.49		0.6	-0.52	0.34	0.38	-0.57	-0.23	-0.54
Short Long Term Debt	-0.82	-0.29	-0.06	0.71	-0.67	-0.6	-0.81	-0.69	-0.77	-0.46	-0.83	-0.85	-0.5	0.53	-0.26	0.6		-0.56	-0.04	0.04	-0.53	-0.41	-0.37
Capital Surpluse	0.85	-0.07	0.39	-0.91	0.49	0.81	0.63	0.87	0.21	0.76	0.36	0.47	0.15	-0.59	0.51	-0.52	-0.56		0.37	0.13	0.97	0.82	0.83
Net Invested Capital	0.41	0.62	-0.18	-0.14	0.14	0.06	0.53	0.21	0.0	0.03	0.04	0.02	0.64	0.44	0.03	0.34	-0.04	0.37		0.94	0.26	0.29	-0.01
Net Working Capital	0.23	0.68	-0.41	0.05	0.18	-0.13	0.45	0.01	0.05	-0.19	0.09	0.01	0.63	0.57	-0.06	0.38	0.04	0.13	0.94		0.0	-0.01	-0.3
Capital Stock	0.8	-0.21	0.56	-0.93	0.41	0.88	0.55	0.93	0.17	0.87	0.28	0.42	0.04	-0.69	0.48	-0.57	-0.53	0.97	0.26	0.0		0.84	0.89
Net Receivables	0.67	-0.13	0.57	-0.75	0.18	0.7	0.41	0.76	0.08	0.73	0.04	0.18	0.08	-0.53	0.38	-0.23	-0.41	0.82	0.29	-0.01	0.84		0.81
Long Term Debt Total	0.63	-0.37	0.69	-0.78	0.3	0.78	0.3	0.77	-0.14	0.81	0.11	0.3	-0.15	-0.7	0.37	-0.54	-0.37	0.83	-0.01	-0.3	0.89	0.81

	2020	2021	2022	2023	2024	2025 (projected)
Asset Turnover	0.0969	0.41	0.0204	0.35	0.32	0.16
Gross Profit Margin	(1.32)	(1.73)	0.99	0.86	0.89	0.94
Net Debt	(75.3M)	(130.8M)	(440K)	86.0M	98.9M	103.8M
Total Current Liabilities	46.4M	82.3M	85.6M	98.7M	113.5M	119.1M
Non Current Liabilities Total	121.8M	141.1M	252.4M	304.8M	350.5M	368.0M
Total Assets	342.9M	354.9M	348.8M	358.6M	412.4M	225.8M
Total Current Assets	268.8M	303.6M	194.8M	175.4M	201.7M	166.7M
Total Cash From Operating Activities	(93.6M)	6.7M	(228.8M)	(117.4M)	(105.6M)	(100.3M)

	Return On Equity	-15.56
	Return On Asset	-0.097
	Profit Margin	(0.20) %
	Operating Margin	(0.34) %
	Current Valuation	161.65 M
	Shares Outstanding	170.74 M
	Shares Owned By Insiders	13.19 %
	Shares Owned By Institutions	37.00 %
	Number Of Shares Shorted	17.46 M
	Price To Earning	(4.04) X
	Price To Book	5.64 X
	Price To Sales	1.07 X
	Revenue	126.33 M
	Gross Profit	(12.61 M)
	EBITDA	(94.31 M)
	Net Income	(113.72 M)
	Cash And Equivalents	195.8 M
	Cash Per Share	1.58 X
	Total Debt	213.94 M
	Debt To Equity	3.35 %
	Current Ratio	2.35 X
	Book Value Per Share	0.14 X
	Cash Flow From Operations	(117.35 M)
	Short Ratio	7.90 X
	Earnings Per Share	(0.40) X
	Price To Earnings To Growth	(0.11) X
	Target Price	3.87
	Number Of Employees	233
	Beta	2.1
	Market Capitalization	134.8 M
	Total Asset	358.6 M
	Retained Earnings	(978.24 M)
	Working Capital	76.75 M
	Current Asset	207.61 M
	Current Liabilities	10.92 M
	Net Asset	358.6 M

Seres Therapeutics Stock Probability Of Bankruptcy

Seres Therapeutics Company chance of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current Seres Therapeutics Probability Of Bankruptcy

Seres Probability Of Bankruptcy Driver Correlations

Seres Probability Of Bankruptcy Peer Comparison

Seres Therapeutics Main Bankruptcy Drivers

Seres Fundamentals

About Seres Therapeutics Fundamental Analysis

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY